Home Alzheimer’s Disease DFS Boost Is Observed With Nivolumab Following Surgery for MIUC

DFS Boost Is Observed With Nivolumab Following Surgery for MIUC

Patients with muscle-invasive urothelial carcinoma (MIUC) benefitted from adjuvant nivolumab (Opdivo) in terms of improved disease-free survival (DFS) versus placebo, according to results of the phase 3 CheckMate 274 trial (NCT02632409).

Investigators found that nivolumab following surgery conferred a median DFS benefit in both the intent-to-treat (ITT) and PD-L1­–positive populations. In the ITT population, DFS in those treated with nivolumab was 21.0 months compared with 10.9 months with placebo (HR, 0.70; 98.31% CI, 0.54-0.89; P < .001).

“This corresponds to a 30% reduction in the risk of disease recurrence or death with nivolumab,” lead author Dean Bajorin, MD, the Frederick R. Adler Senior Faculty Chair at Memorial Sloan Kettering Cancer Center in New York, New York, said during a presentation of the data at the 2021 ASCO Genitourinary Cancers Symposium. “The median DFS is…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments